1
|
Abstract
Recent years have witnessed an emergence of interest in understanding metabolic changes associated with immune responses, termed immunometabolism. As oxygen is central to all aerobic metabolism, hypoxia is now recognized to contribute fundamentally to inflammatory and immune responses. Studies from a number of groups have implicated a prominent role for oxygen metabolism and hypoxia in innate immunity of healthy tissue (physiologic hypoxia) and during active inflammation (inflammatory hypoxia). This inflammatory hypoxia emanates from a combination of recruited inflammatory cells (e.g., neutrophils, eosinophils, and monocytes), high rates of oxidative metabolism, and the activation of multiple oxygen-consuming enzymes during inflammation. These localized shifts toward hypoxia have identified a prominent role for the transcription factor hypoxia-inducible factor (HIF) in the regulation of innate immunity. Such studies have provided new and enlightening insight into our basic understanding of immune mechanisms, and extensions of these findings have identified potential therapeutic targets. In this review, we summarize recent literature around the topic of innate immunity and mucosal hypoxia with a focus on transcriptional responses mediated by HIF.
Collapse
Affiliation(s)
- Sean P Colgan
- Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado 80045, USA;
- Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Glenn T Furuta
- Mucosal Inflammation Program, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
| | - Cormac T Taylor
- UCD Conway Institute, Systems Biology Ireland and School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland
| |
Collapse
|
2
|
Van Welden S, De Vos M, Wielockx B, Tavernier SJ, Dullaers M, Neyt S, Descamps B, Devisscher L, Devriese S, Van den Bossche L, Holvoet T, Baeyens A, Correale C, D'Alessio S, Vanhove C, De Vos F, Verhasselt B, Breier G, Lambrecht BN, Janssens S, Carmeliet P, Danese S, Elewaut D, Laukens D, Hindryckx P. Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. J Pathol 2017; 241:547-558. [PMID: 27981571 DOI: 10.1002/path.4861] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2016] [Revised: 11/21/2016] [Accepted: 12/06/2016] [Indexed: 12/17/2022]
Abstract
Prolyl hydroxylase domain-containing proteins (PHDs) regulate the adaptation of cells to hypoxia. Pan-hydroxylase inhibition is protective in experimental colitis, in which PHD1 plays a prominent role. However, it is currently unknown how PHD1 targeting regulates this protection and which cell type(s) are involved. Here, we demonstrated that Phd1 deletion in endothelial and haematopoietic cells (Phd1f/f Tie2:cre) protected mice from dextran sulphate sodium (DSS)-induced colitis, with reduced epithelial erosions, immune cell infiltration, and colonic microvascular dysfunction, whereas the response of Phd2f/+ Tie2:cre and Phd3f/f Tie2:cre mice to DSS was similar to that of their littermate controls. Using bone marrow chimeras and cell-specific cre mice, we demonstrated that ablation of Phd1 in haematopoietic cells but not in endothelial cells was both necessary and sufficient to inhibit experimental colitis. This effect relied, at least in part, on skewing of Phd1-deficient bone marrow-derived macrophages towards an anti-inflammatory M2 phenotype. These cells showed an attenuated nuclear factor-κB-dependent response to lipopolysaccharide (LPS), which in turn diminished endothelial chemokine expression. In addition, Phd1 deficiency in dendritic cells significantly reduced interleukin-1β production in response to LPS. Taken together, our results further support the development of selective PHD1 inhibitors for ulcerative colitis, and identify haematopoietic cells as their primary target. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
| | - Martine De Vos
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Ben Wielockx
- Heisenberg Research Group, Department of Clinical Pathobiochemistry, Institute for Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany
| | - Simon J Tavernier
- Department of Internal Medicine, Ghent University, Ghent, Belgium.,Inflammation Research Centre VIB, Zwijnaarde, Belgium
| | - Melissa Dullaers
- Inflammation Research Centre VIB, Zwijnaarde, Belgium.,Department of Pulmonary Medicine, Ghent University, Ghent, Belgium
| | - Sara Neyt
- Laboratory of Radiopharmacy, Ghent University, Ghent, Belgium
| | - Benedicte Descamps
- Infinity Imaging Laboratory (iMinds Medical IT-IBiTech-MEDISIP), Ghent University, Ghent, Belgium
| | | | - Sarah Devriese
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | | | - Tom Holvoet
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Ann Baeyens
- Department of Clinical Chemistry, Microbiology, and Immunology, Ghent University, Ghent, Belgium
| | - Carmen Correale
- IBD Centre, Department of Gastroenterology, Humanitas Clinical and Research Centre, Rozzano, Italy
| | - Silvia D'Alessio
- IBD Centre, Department of Gastroenterology, Humanitas Clinical and Research Centre, Rozzano, Italy
| | - Christian Vanhove
- Infinity Imaging Laboratory (iMinds Medical IT-IBiTech-MEDISIP), Ghent University, Ghent, Belgium
| | - Filip De Vos
- Laboratory of Radiopharmacy, Ghent University, Ghent, Belgium
| | - Bruno Verhasselt
- Department of Clinical Chemistry, Microbiology, and Immunology, Ghent University, Ghent, Belgium
| | - Georg Breier
- Division of Medical Biology, Department of Psychiatry, Technische Universität Dresden, Dresden, Germany
| | - Bart N Lambrecht
- Department of Internal Medicine, Ghent University, Ghent, Belgium.,Inflammation Research Centre VIB, Zwijnaarde, Belgium
| | - Sophie Janssens
- Department of Internal Medicine, Ghent University, Ghent, Belgium.,Inflammation Research Centre VIB, Zwijnaarde, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Vascular metabolism, Vesalius Research Centre, KU Leuven, VIB, Leuven, Belgium
| | - Silvio Danese
- IBD Centre, Department of Gastroenterology, Humanitas Clinical and Research Centre, Rozzano, Italy
| | - Dirk Elewaut
- Inflammation Research Centre VIB, Zwijnaarde, Belgium.,Department of Rheumatology, Ghent University, Ghent, Belgium
| | - Debby Laukens
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| | - Pieter Hindryckx
- Department of Gastroenterology, Ghent University, Ghent, Belgium
| |
Collapse
|
3
|
Gupta R, Chaudhary AR, Shah BN, Jadhav AV, Zambad SP, Gupta RC, Deshpande S, Chauthaiwale V, Dutt C. Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis. Clin Exp Gastroenterol 2014; 7:13-23. [PMID: 24493931 PMCID: PMC3908906 DOI: 10.2147/ceg.s51923] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND AND AIM Mucosal healing in inflammatory bowel disease (IBD) can be achieved by improvement of intestinal barrier protection. Activation of hypoxia-inducible factor (HIF) has been identified as a critical factor for barrier protection during mucosal insult and is linked with improvement in symptoms of colitis. Although prophylactic efficacy of HIF hydroxylase inhibitors in murine colitis have been established, its therapeutic efficacy in clinically relevant therapeutic settings have not been established. In the present study we aim to establish therapeutic efficacy of TRC160334, a novel HIF hydroxylase inhibitor, in animal models of colitis. METHODS The efficacy of TRC160334 was evaluated in two different mouse models of colitis by oral route. A prophylactic efficacy study was performed in a 2,4,6-trinitrobenzene sulfonic acid-induced mouse model of colitis representing human Crohn's disease pathology. Additionally, a therapeutic efficacy study was performed in a dextran sulfate sodium-induced mouse model of colitis, a model simulating human ulcerative colitis. RESULTS TRC160334 treatment resulted in significant improvement in disease end points in both models of colitis. TRC160334 treatment resulted into cytoprotective heatshock protein 70 induction in inflamed colon. TRC160334 successfully attenuated the rate of fall in body weight, disease activity index, and macroscopic and microscopic scores of colonic damage leading to overall improvement in study outcome. CONCLUSION Our findings are the first to demonstrate that therapeutic intervention with a HIF hydroxylase inhibitor ameliorates IBD in disease models. These findings highlight the potential of TRC160334 for its clinical application in the treatment of IBD.
Collapse
Affiliation(s)
- Ram Gupta
- Department of Pharmacology, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Anita R Chaudhary
- Cellular and Molecular Biology, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Binita N Shah
- Department of Pharmacology, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Avinash V Jadhav
- Preclinical Safety Evaluation, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Shitalkumar P Zambad
- Department of Pharmacology, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Ramesh Chandra Gupta
- Discovery, Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Shailesh Deshpande
- Discovery, Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Vijay Chauthaiwale
- Discovery, Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| | - Chaitanya Dutt
- Discovery, Torrent Research Centre, Torrent Pharmaceuticals Ltd, Gandhinagar, Gujarat, India
| |
Collapse
|
4
|
Qiu HJ, Wu W, Liu ZJ. Role of hypoxic injury in pathophysiology of intestinal mucosal inflammation. Shijie Huaren Xiaohua Zazhi 2013; 21:591-596. [DOI: 10.11569/wcjd.v21.i7.591] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Hypoxia influences the normal metabolism of cells and normal functions of organs, eventually causing diseases. Various degrees of hypoxia can be seen in the intestinal mucosa of both experimental mouse models and patients with inflammatory bowel disease (IBD), whose oxygen supply and oxygen consumption are damaged. A number of hypoxia inducible factors, such as HIF-1, HIF-2 and HIF-3, can regulate different physiological responses via different mechanisms. Proline hydroxylasedomain (PHD) is a two-dioxygenase oxygen sensor that can mediate degradation of proline residues of HIFs. IBD is closely related to hypoxia. In recent years, researchers have paid more attention to improving the body's reaction to hypoxia in IBD, which is considered a novel treatment concept. This review will analyze the role of hypoxic injury in the pathophysiology of intestinal mucosal inflammation in IBD.
Collapse
|